<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637763</url>
  </required_header>
  <id_info>
    <org_study_id>CB10A</org_study_id>
    <nct_id>NCT04637763</nct_id>
  </id_info>
  <brief_title>CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caribou Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caribou Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity&#xD;
      of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after&#xD;
      lymphodepletion consisting of cyclophosphamide and fludarabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a first-in-human, Phase 1, multicenter, open-label evaluation of&#xD;
      safety and emerging efficacy of CB-010 in adults with relapsed/refractory B cell non-Hodgkin&#xD;
      lymphoma. The study is conducted in two parts: Part A is dose escalation following a 3 + 3&#xD;
      design, with sequential, prespecified, increasing doses. Part B is the expansion portion&#xD;
      where patients will receive CB-010 at the dose determined in Part A.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The CB10A clinical study consists of 3 + 3 design with three dose levels.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measures number of patients with dose-limiting toxicities (Part A).</measure>
    <time_frame>28 days following CB-010 infusion</time_frame>
    <description>Incidence of adverse events defined as dose-limiting toxicities with onset within 28 days after CB-010 infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary outcome evaluates tumor response (Part B)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The primary endpoint is objective response rate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Lymphoma</condition>
  <condition>B Cell Lymphoma</condition>
  <condition>B Cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation of CB-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion of CB-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CB-010</intervention_name>
    <description>CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.</description>
    <arm_group_label>Dose Escalation of CB-010</arm_group_label>
    <arm_group_label>Expansion of CB-010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>Dose Escalation of CB-010</arm_group_label>
    <arm_group_label>Expansion of CB-010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>Dose Escalation of CB-010</arm_group_label>
    <arm_group_label>Expansion of CB-010</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 at the time of enrollment&#xD;
&#xD;
          -  Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior&#xD;
             standard of care&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          -  Adequate hematologic, renal, liver, cardiac and pulmonary organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with an anti-CD19 targeting agent&#xD;
&#xD;
          -  Active or chronic graft versus host disease requiring therapy&#xD;
&#xD;
          -  Prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  Central nervous system (CNS) lymphoma, prior CNS malignancy&#xD;
&#xD;
          -  Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or&#xD;
             autoimmune disease with CNS involvement.&#xD;
&#xD;
          -  Primary immunodeficiency&#xD;
&#xD;
          -  Current or expected need for systemic corticosteroid therapy&#xD;
&#xD;
          -  Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is&#xD;
             permitted&#xD;
&#xD;
          -  Other malignancy within 2 years of study entry, except curatively treated malignancies&#xD;
             or malignancies with low risk of recurrence&#xD;
&#xD;
          -  Unwillingness to follow extended safety monitoring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cherry Thomas, MD</last_name>
    <phone>510-926-9893</phone>
    <email>ClinicalTrials@CaribouBio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Padilla</last_name>
      <phone>858-822-5223</phone>
      <email>mlp002@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center/University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Johnson</last_name>
      <phone>714-456-3476</phone>
      <email>blakej@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Clayton</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27135</phone_ext>
      <email>Eric.Clayton@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarah Satterfield</last_name>
      <phone>214-818-8472</phone>
      <email>Tarah.Satterfield@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ly Dsouza</last_name>
      <phone>713-745-8614</phone>
      <email>ldsouza@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

